Minimal Residual Disease By PCR Testing Is a Significant Predictor of Disease Relapse in Patients with FLT3 Positive AML after Hematopoietic Stem Cell Transplantation
Year: 2015
Type: article
Abstract: FLT3 mutations are present in up to 30% of AML pts with diploid cytogenetics. Allogeneic hematopoietic stem cell transplantation (AlloSCT) has emerged as the preferred therapy for this high-risk group, but these pts remain at high risk for disease relapse. The significance of FLT3 detection by PCR, as a minimal residual disease marker, at the time of AlloSCT remains unclear and little is known about the risk factors associated with risk of relapse among FLT3 AML pts.
Authors: Sameh Gaballa, Rima Saliba, Betul Oran, Jonathan E. Brammer, Julianne Chen, Gabriela Rondon, Amin M. Alousi, Partow Kebriaei, Uday R. Popat, Borje S. Andersson, Elizabeth J. Shpall, Elias Jabbour, Naval Daver, Michael Andreeff, Farhad Ravandi, Jorge Cortes, Richard E. Champlin, Stefan O. Ciurea
Institution: The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,650
OpenAlex ID: W2061778366